# Effect of Evolocumab on Coronary Atherosclerosis

> **NCT03689946** · PHASE3 · COMPLETED · sponsor: **Cedars-Sinai Medical Center** · enrollment: 55 (actual)

## Conditions studied

- Cardiovascular Disease
- Hyperlipidemia

## Interventions

- **DRUG:** Evolocumab
- **DIAGNOSTIC_TEST:** 18F-NaF PET
- **DIAGNOSTIC_TEST:** CCTA
- **DRUG:** Omnipaque
- **DRUG:** Metoprolol
- **DRUG:** Nitroglycerin

## Key facts

- **NCT ID:** NCT03689946
- **Lead sponsor:** Cedars-Sinai Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-03-19
- **Primary completion:** 2023-01-28
- **Final completion:** 2023-05-30
- **Target enrollment:** 55 (ACTUAL)
- **Last updated:** 2024-07-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03689946

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03689946, "Effect of Evolocumab on Coronary Atherosclerosis". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT03689946. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*